&nbsp;

ocs2020-man-2.png

Mar 2020

Document

ocs2020-man-3.png

Mar 2020

Document

ocs2020-woman-3.png

Mar 2020

Guidelines and Advice

Regional Therapies for Colorectal Cancer Liver Metastases

Status: Current
ID: GL 2-30a
Version: N/A

Mar 2020

Regimen

DARO

Cancer Type:

Genitourinary,

Prostate

Intent: Palliative

Funding:

Exceptional Access Program

darolutamide - For the treatment of high risk non-metastatic castration resistant prostate cancer (nmCRPC) according to clinical criteria

Drugs Used:

darolutamide

Quick Link(s):

Regimen Monograph

Mar 2024

Regimen

LOMU+BEVA

Cancer Type:

Central Nervous System

Intent: Palliative

Funding:

ODB - General Benefit

lomustine

New Drug Funding Program

Bevacizumab (Biosimilar) - In Combination with Lomustine for Recurrent Glioblastoma

Drugs Used:

lomustine,

bevacizumab

Quick Link(s):

Regimen Monograph

Regimen

BELA

Cancer Type:

Hematologic,

Multiple Myeloma

Intent: Palliative

Drugs Used:

belantamab mafodotin (Unfunded)

Quick Link(s):

Regimen Monograph

Mar 2020

Regimen

GDP+OBIN

Cancer Type:

Hematologic,

Lymphoma - Non-Hodgkin's Low Grade

Intent: Palliative

Funding:

New Drug Funding Program

Obinutuzumab - In Combination with Chemotherapy for Refractory Follicular Lymphoma

ODB - General Benefit

dexamethasone

Drugs Used:

Quick Link(s):

Regimen Monograph

Mar 2020

Regimen

CYTA(SC)

Cancer Type:

Hematologic,

Leukemia - Acute Myeloid (AML)

Intent: Palliative

Drugs Used:

cytarabine (Unfunded)

Quick Link(s):

Regimen Monograph

Mar 2020

Regimen

MTRX(HD)

Cancer Type:

Hematologic,

Lymphoma - Non-Hodgkin's High Grade

Intent: Curative

Drugs Used:

methotrexate,

leucovorin

Quick Link(s):

Regimen Monograph

Guidelines and Advice

Minimal Residual Disease Testing in Acute Leukemia

Status: Current
ID: MOTAC-6
Version: 2

Sep 2020

Document